PHARMOS NDA FILING FOR FIRST PRODUCT, LENOXIN
PHARMOS NDA FILING FOR FIRST PRODUCT, LENOXIN, is projected for late 1994. The corticosteroid is designed for treatment of conjunctivitis associated with contact lens wear and allergies; results from Phase III clinical studies were presented by Phannos at an April 27 press conference in New York City. The Phase III results indicate that Lenoxin (lotepredol etabonate) has a lower incidence of side effects -- primarily elevated intraocular pressure -- compared to ophthalmic steroids now on the market, such as prednisolone and dexamethasone.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth